Results from the VALENTINE-PTCL01 Phase 2 trial of EZHARMIA® showed clinically meaningful and durable responses in patients with relapsed or refractory peripheral T-cell lymphoma.
Results from the VALENTINE-PTCL01 phase 2 trial of Daiichi Sankyo’s EZHARMIA® (valemetostat tosilate) showed clinically meaningful and durable responses in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The data were presented in an oral session at the 2023…